The Neoadjuvant Administration of PD-1 Inhibitor plus Concurrent Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous-Cell Carcinoma

Table 5

Adverse events.

Events	Total, no. (%)	Grade 1-2, no. (%)	Grade 3-4, no. (%)
Fatigue	12 (48.0)	12 (48.0)	0 (0.0)
Nausea and vomiting	10 (40.0)	9 (36.0)	1 (4.0)
Leukopenia	9 (36.0)	8 (32.0)	1 (4.0)
Neutropenia	9 (36.0)	8 (32.0)	1 (4.0)
Peripheral neuropathy	9 (36.0)	6 (24.0)	3 (12.0)
Anemia	8 (32.0)	7 (28.0)	1 (4.0)
Pruritus	8 (32.0)	7 (28.0)	1 (4.0)
Hand-foot syndrome	8 (32.0)	8 (32.0)	0 (0.0)
Elevated transaminase	7 (28.0)	7 (28.0)	0 (0.0)
Diarrhea	5 (20.0)	5 (20.0)	0 (0.0)
Thrombocytopenia	4 (16.0)	4 (16.0)	0 (0.0)
Fever	4 (16.0)	4 (16.0)	0 (0.0)
Anorexia	4 (16.0)	4 (16.0)	0 (0.0)
Hypertension	4 (16.0)	4 (16.0)	0 (0.0)
Elevated bilirubin	3 (12.0)	3 (12.0)	0 (0.0)